AstraZeneca is looking for partnerships in oncology
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. They discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Their research has breadth, and depth and focuses on disease areas where AstraZeneca and their partners can make the most meaningful impact on patients’ lives. Innovative Medicine’s Units (iMeds) are responsible for driving research from discovery to early development in their core therapeutic areas, while New Opportunities group looks for strategic areas of focus outside their core disease areas.
For more than 30 years, AstraZeneca has remained committed to pushing the boundaries of cancer research and delivering the cancer therapies of tomorrow.They’re taking an innovative patient-based approach to treatment, and drawing on partnerships across the globe with academia, governments, scientific organisations and patient groups, as well as other biopharmaceutical companies. Their small and large molecule research focuses on cancer of the breast, prostate, gastrointestinal tract, lung, as well as haematological malignancies, “niche” cancers, novel technologies and biomarkers.